24,773 results match your criteria Breast Cancer and HER2


Phase I Trial of a Novel Anti-HER2 Antibody-Drug Conjugate, ARX788, for the Treatment of HER2-Positive Metastatic Breast Cancer.

Clin Cancer Res 2022 Jun 29:OF1-OF10. Epub 2022 Jun 29.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

Purpose: ARX788 is a novel antibody-drug conjugate (ADC) comprised of an anti-HER2 mAb and a potent tubulin inhibitor payload AS269 that is site-specifically conjugated to the antibody via a nonnatural amino acid incorporated into the antibody. Herein, we present the results of a phase I study of the safety, pharmacokinetics, and antitumor activity of ARX788 in patients with HER2-positive metastatic breast cancer (MBC).

Patients And Methods: Patients with HER2-positive MBC received ARX788 at doses of 0. Read More

View Article and Full-Text PDF

Gene-Gene Interaction Study Between Genetic Polymorphisms of Folate Metabolism and MTR SNPs on Prognostic Features Impact for Breast Cancer.

Rep Biochem Mol Biol 2022 Apr;11(1):89-101

Chemistry Department, Faculty of Science, Helwan University, Cairo, Egypt (11795).

Background: Breast Cancer (BC), the second leading cause of cancer mortality after lung cancer and varied across the world due to genetic and environmental factors. In this study, we evaluated the interaction between the polymorphisms in genes encoding enzymes of folate metabolism: methylenetetrahydrofolate reductase (), methionine synthesis reductase () with the BC prognostic factors.

Methods: This study was conducted on 160 Egyptian subjects, 60 controls and 100 cases. Read More

View Article and Full-Text PDF

The Complexity of Response to the Proliferation Agonist and Antagonist Agents, in the Breast Cancer Cell Lines with Various Receptors.

Iran J Pharm Res 2022 Dec 16;21(1):e123823. Epub 2022 Feb 16.

Department of Toxicology, School of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, Iran.

Breast cancer is a heterogeneous disease in which many factors and receptors are effective in the disease process and response to treatment. Currently, estrogen, progesterone, and HER2 receptors are among the most important factors in choosing a treatment regimen. Other metabolic factors that may affect the treatment outcome include diabetes and hyperinsulinemia. Read More

View Article and Full-Text PDF
December 2022

Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial.

J Clin Oncol 2022 Jun 28:JCO2102772. Epub 2022 Jun 28.

Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY.

Purpose: Combining standard of care (pertuzumab-trastuzumab [PH], chemotherapy) with cancer immunotherapy may potentiate antitumor immunity, cytotoxic activity, and patient outcomes in high-risk, human epidermal growth factor receptor 2 (HER2)-positive early breast cancer. We report the phase III IMpassion050 primary analysis of neoadjuvant atezolizumab, PH, and chemotherapy in these patients.

Methods: Patients with a primary tumor of > 2 cm and histologically confirmed, positive lymph node status (T2-4, N1-3, M0) were randomly assigned 1:1 to atezolizumab/placebo with dose-dense doxorubicin/cyclophosphamide, followed by paclitaxel, and PH. Read More

View Article and Full-Text PDF

Expression of PD-L1 in Locally Advanced Breast Cancer and Its Impact on Neoadjuvant Chemotherapy Response.

Asian Pac J Cancer Prev 2022 Jun 1;23(6):2095-2103. Epub 2022 Jun 1.

Department of Pathology, National Cancer Institute, Cairo University, Egypt.

Objectives: Programmed cell death-ligand 1 (PD-L1) is a new target in breast cancer (BC) and its impact on neoadjuvant chemotherapy (NACTH) response is still unclear. The aim of this study was to investigate the prevalence of PD-L1 in locally advanced invasive BC of different molecular subtypes and to elucidate its relation to tumor-infiltrating lymphocytes (TILs) density, established clinicopathological factors, pathological therapy response after neoadjuvant chemotherapy and patients' outcome.

Materials And Methods: One hundred and five cases of locally advanced invasive BC were enrolled in our study. Read More

View Article and Full-Text PDF

Sentinel Lymph Node Biopsy Alone is Adequate for Chemotherapy Decisions in Postmenopausal Early-Stage Hormone-Receptor-Positive, HER2-Negative Breast Cancer with One to Three Positive Sentinel Lymph Nodes.

Ann Surg Oncol 2022 Jun 28. Epub 2022 Jun 28.

Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Boston, MA, USA.

Background: The RxPONDER trial randomized patients with cT1-3N0 hormone receptor-positive, HER2-negative (HRHER2) breast cancer and one to three positive nodes and Recurrence Score (RS) < 26 to endocrine therapy (ET) or chemoendocrine therapy (CET) with equivalent survival in postmenopausal women. In current practice, cN0 patients with one or two positive sentinel lymph nodes (SLN) do not undergo axillary lymph node dissection (ALND), raising concerns about applying these data in patients who may have additional nodal disease.

Methods: We identified institutional [Dana-Farber Brigham Cancer Center (DF/BCC), 2016-2020] and national [National Cancer Database (NCDB), 2012-2017] cohorts of women aged 50-75 years with cT1-3N0 HRHER2 breast cancer and RS < 26 treated with upfront surgery with one to three positive SLN. Read More

View Article and Full-Text PDF

Expression of ERBB gene family in females with breast cancer and its correlation with clinicopathological characteristics of the disease.

Mol Biol Rep 2022 Jun 28. Epub 2022 Jun 28.

Genetics Research Center, University of Social Welfare and Rehabilitation Sciences, Tehran, Iran.

Background: Breast cancer (BC) is the most prevalent and fatal cancer in women. Given that there are very few studies investigating the overexpression of four members of ERBB genes, we decided to investigate the correlation between these four genes with clinicopathological characteristics in breast cancer cases.

Methods: Tumoural tissue of 50 patients with sporadic invasive ductal BC was recruited. Read More

View Article and Full-Text PDF

An evaluation of lymphovascular invasion in relation to biology and prognosis according to subtypes in invasive breast cancer.

Oncol Lett 2022 Aug 7;24(2):245. Epub 2022 Jun 7.

Department of Pathology, Kumamoto Shinto General Hospital, Kumamoto, Kumamoto 862-8655, Japan.

Lymphovascular invasion (LVI) is associated with a poor outcome in breast cancer. The purpose of the present study was to evaluate the clinical significance of LVI in primary breast cancer and to investigate disease-free survival as a prognostic marker according to the breast cancer subtypes. This study examined 4,652 consecutive cases of invasive breast cancer excluding the patients with non-invasive cancer, stage IV and those who underwent neo-adjuvant therapy from February 2002 to February 2021. Read More

View Article and Full-Text PDF

Triple-negative breast cancer drug resistance, durable efficacy, and cure: How advanced biological insights and emerging drug modalities could transform progress.

Expert Opin Ther Targets 2022 Jun 27. Epub 2022 Jun 27.

Department of Pharmacy, Health and Nutritional Sciences, University of Calabria, 87036 Rende, Italy.

Introduction: Triple-negative breast cancer (TNBC) is a heterogeneous disease characterized by the lack of estrogen receptor (ER), progesterone receptor (PR) and epidermal growth factor receptor 2 (HER2) and often associated with poor survival outcomes. The backbone of current treatments for TNBC relies on chemotherapy; however, resistance to cytotoxic agents is a commonly encountered hurdle to overcome.

Areas Covered: : Current understanding on the mechanisms involved in TNBC chemoresistance is evaluated and novel potential actionable targets and recently explored modalities for carrying and delivering chemotherapeutics are highlighted. Read More

View Article and Full-Text PDF

The SKBR3 cell-membrane proteome reveals telltales of aberrant cancer cell proliferation and targets for precision medicine applications.

Sci Rep 2022 Jun 27;12(1):10847. Epub 2022 Jun 27.

Department of Biological Sciences, Virginia Tech, Blacksburg, VA, 24061, USA.

The plasma membrane proteome resides at the interface between the extra- and intra-cellular environment and through its various roles in signal transduction, immune recognition, nutrient transport, and cell-cell/cell-matrix interactions plays an absolutely critical role in determining the fate of a cell. Our work was aimed at exploring the cell-membrane proteome of a HER2+ breast-cancer cell line (SKBR3) to identify triggers responsible for uncontrolled cell proliferation and intrinsic resources that enable detection and therapeutic interventions. To mimic environmental conditions that enable cancer cells to evolve adaptation/survival traits, cell culture was performed under serum-rich and serum-deprived conditions. Read More

View Article and Full-Text PDF

Dissecting the Interplay Between Genetic Ancestry and Neighborhood Socioeconomic Status on Triple Negative Breast Cancer.

Ann Surg 2022 Jun 27. Epub 2022 Jun 27.

Department of Surgery, Division of Surgical Oncology, University of Miami Miller School of Medicine, Miami, Florida, USA.

Objective: To investigate the impact of global and local genetic ancestry and neighborhood socioeconomic status (nSES), on breast cancer (BC) subtype, and gene expression.

Summary Of Background Data: Higher rates of aggressive BC subtypes (TNBC) and worse overall BC survival are seen in black women [Hispanic (HB) and non-Hispanic (NHB)] and women from low nSES. However, the complex relationship between genetic ancestry, nSES, and BC subtype etiology remains unknown. Read More

View Article and Full-Text PDF

Adjuvant therapy for HER2 positive pT1a-b pN0 breast cancer: A single center cohort study.

Medicine (Baltimore) 2022 Jun 24;101(25):e29371. Epub 2022 Jun 24.

Department of Pathology, Shanxi Provincial People's Hospital, Taiyuan Shanxi China.

Abstract: Deciding if patients with small (≤1 cm), node-negative, human epidermal growth factor receptor 2 (HER2) positive breast cancer should receive adjuvant systemic therapy remains a challenge. No randomized clinical trials have examined the efficacy of trastuzumab in this setting. This prospective observational study aimed to investigate the choice of adjuvant systemic therapy in clinical practice in China. Read More

View Article and Full-Text PDF

Palbociclib plus letrozole induces a complete metabolic response in metastatic breast cancer patient with idiopathic thrombocytopenia.

Recenti Prog Med 2022 Jun;113(6):376-379

Division of Medical Oncology 1, Regina Elena National Cancer Institute, Rome, Italy.

Breast cancer is still the leading cause of cancer-related deaths among women aged 20-59 and metastatic breast cancer remains an incurable disease. The therapeutic paradigm of patients with HR-positive HER2-negative metastatic breast cancer has been expanded by the introduction of the inhibitors of cyclin-dependent kinases 4/6. Three compounds, palbociclib, ribociclib, and abemaciclib, have already been approved by the Food and Drug Administration (FDA) for use together with endocrine therapy; abemaciclib is also approved as a single agent. Read More

View Article and Full-Text PDF

Perioperative HER2 targeted treatment in early stage HER2-positive breast cancer.

Ther Adv Med Oncol 2022 21;14:17588359221106564. Epub 2022 Jun 21.

Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-ro, Gangnam-gu, Seoul 06351, Republic of Korea.

Although human epidermal growth factor receptor 2 (HER2)-positive breast cancer was associated with poor prognosis, it has been changed after the development of trastuzumab. There has been great progress in perioperative HER2-targeting treatment, and investigations of several novel drugs and their combinations are ongoing. Adjuvant trastuzumab with or without pertuzumab for 1 year in combination with concomitant chemotherapy has become a standard treatment in high-risk node-negative tumors or node-positive HER2-positive early breast cancer patients without residual disease or who have not received neoadjuvant treatment. Read More

View Article and Full-Text PDF

Toll-like receptor 2 promotes breast cancer progression and resistance to chemotherapy.

Oncoimmunology 2022 15;11(1):2086752. Epub 2022 Jun 15.

Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.

Cancer stem cells (CSCs) are the main drivers of disease progression and chemotherapy resistance in breast cancer. Tumor progression and chemoresistance might then be prevented by CSC-targeted therapies. We previously demonstrated that Toll-like Receptor (TLR)2 is overexpressed in CSCs and fuels their self-renewal. Read More

View Article and Full-Text PDF

Molecular Subtypes As Emerging Predictors of Clinicopathological Response to Neoadjuvant Chemotherapy (NACT) in Locally Advanced Breast Cancer (LABC): A Single-Centre Experience in Western India.

Cureus 2022 May 22;14(5):e25229. Epub 2022 May 22.

General Surgery, Dr. Sampurnanand Medical College, Jodhpur, IND.

Introduction: Locally advanced breast cancer (LABC) is a subset of breast cancer characterized by the most advanced breast tumours in the absence of distant metastasis. Treatment of LABC has evolved from a single modality treatment to multimodality management. Neoadjuvant chemotherapy (NACT) is increasingly being used to treat patients with LABC. Read More

View Article and Full-Text PDF

Pertuzumab retreatment for HER2-positive advanced breast cancer: a randomized, open-label phase III study (PRECIOUS).

Cancer Sci 2022 Jun 26. Epub 2022 Jun 26.

Breast Oncology Center, The Cancer Institute Hospital of the JFCR, Tokyo, Japan.

No standard options existed for HER2-positive advanced breast cancer that progresses after second-line trastuzumab emtansine therapy (T-DM1) before 2020. The purpose of this study was to examine the efficacy of pertuzumab retreatment after disease progression following pertuzumab-containing therapy for HER2-positive locally advanced or metastatic breast cancer for the first time. This randomized, open-label, multicenter phase 3 trial was conducted in 93 sites in Japan. Read More

View Article and Full-Text PDF

Chemokine receptors differentially expressed by race category and molecular subtype in the breast cancer TCGA cohort.

Sci Rep 2022 Jun 26;12(1):10825. Epub 2022 Jun 26.

Department of Biology, San Francisco State University, San Francisco, CA, 94132, USA.

Racial disparities in mortality due to metastasis remain significant among breast cancer patients. Chemokine receptors contribute to breast tumors and metastatic outcome. We explored for significant differences in chemokine receptor expression in breast tumors from Black, Asian, and White patients in The Cancer Genome Atlas. Read More

View Article and Full-Text PDF

Engineered nanomaterials as an effective tool for HER2+ breast cancer therapy.

Drug Discov Today 2022 Jun 23. Epub 2022 Jun 23.

Department of Pharmaceutical Sciences, Babasaheb Bhimrao Ambedkar University (A Central University), Lucknow-226025, India. Electronic address:

Breast cancer (BC) is the second most common cancer in women, with a high morbidity rate. The human epidermal growth factor receptor HER2 is a growth-promoting protein that is overexpressed in 15-20% of breast cancers (HER2+ BCs) and is often associated with clinically aggressive disease. Targeting this oncogene has resulted in significant improvements in survival outcomes for HER2+ BC patients. Read More

View Article and Full-Text PDF

Prevalence of Pathologic N2/N3 Disease in Postmenopausal Women with Clinical N0 ER+/HER2- Breast Cancer.

Ann Surg Oncol 2022 Jun 25. Epub 2022 Jun 25.

Department of Surgery, University of North Carolina, Chapel Hill, NC, USA.

Background: The RxPONDER trial demonstrated that the 21-gene recurrence score can be used to guide adjuvant systemic therapy decisions in postmenopausal women with pN1 ER+/HER2- breast cancer. As such, a sentinel lymph node biopsy (SLNB) may not provide systemic treatment-altering information for many patients, and omission of SLNB in patients with low probability of pN2/N3 disease could be considered.

Methods: Postmenopausal women (aged ≥ 50 years) diagnosed with cN0cM0, ER+/HER- breast cancer from 2013 to 2017 were identified in the National Cancer Database. Read More

View Article and Full-Text PDF

Neoadjuvant afatinib with paclitaxel for triple-negative breast cancer and the molecular characteristics in responders and non-responders.

J Formos Med Assoc 2022 Jun 22. Epub 2022 Jun 22.

Department of Surgery, National Taiwan University Hospital, Taipei, Taiwan; Department of Surgery, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address:

Background: The prognosis of triple-negative breast cancer (TNBC) is worse and a major proportion of TNBC expresses epidermal growth factor receptor (EGFR). Afatinib can inhibit EGFR signal pathway; however, its treatment effect for TNBC is unknown. Thus, we aimed to assess the efficacy and biomarkers of afatinib in combination with paclitaxel in a neoadjuvant setting. Read More

View Article and Full-Text PDF

Update on prognostic and predictive biomarkers of breast cancer.

Semin Diagn Pathol 2022 Jun 18. Epub 2022 Jun 18.

Department of pathology, The Ohio State University Wexner Medical Center, Columbus OH. Electronic address:

Breast cancer represents a heterogeneous group of human cancer at both histological and molecular levels. Estrogen receptor (ER), progesterone receptor (PR) and human epidermal growth factor receptor 2 (HER2) are the most commonly used biomarkers in clinical practice for making treatment plans for breast cancer patients by oncologists. Recently, PD-L1 testing plays an important role for immunotherapy for triple-negative breast cancer. Read More

View Article and Full-Text PDF

Multidisciplinary Team Meeting Proposal and Final Therapeutic Choice in Early Breast Cancer: Is There an Agreement?

Front Oncol 2022 7;12:885992. Epub 2022 Jun 7.

Department of Medical Oncology, Academic Hospital of Udine, Udine, Italy.

Background: A multidisciplinary team meeting (MDM) approach in breast cancer (BC) management is a standard of care. One of the roles of MDMs is to identify the best diagnostic and therapeutic strategies for patients (pts) with new diagnosis of early BC. The purpose of this study was to define whether there was an agreement between the planned program (i. Read More

View Article and Full-Text PDF

[Tc]Tc-iFAP/SPECT Tumor Stroma Imaging: Acquisition and Analysis of Clinical Images in Six Different Cancer Entities.

Pharmaceuticals (Basel) 2022 Jun 9;15(6). Epub 2022 Jun 9.

Department of Radioactive Materials, Instituto Nacional de Investigaciones Nucleares, Ocoyoacac 52750, Mexico.

Fibroblast activation protein (FAP) is highly expressed on the cancer-associated fibroblasts (CAF) of the tumor stroma. Recently, we reported the preclinical evaluation and clinical biokinetics of a novel Tc-labeled FAP inhibitor radioligand ([Tc]Tc-iFAP). This research aimed to evaluate [Tc]Tc-iFAP for the tumor stroma imaging of six different cancerous entities and analyze them from the perspective of stromal heterogeneity. Read More

View Article and Full-Text PDF

Signaling Pathways and Natural Compounds in Triple-Negative Breast Cancer Cell Line.

Molecules 2022 Jun 7;27(12). Epub 2022 Jun 7.

Department of Pharmaceutical Analysis and Medicinal Chemistry, Faculty of Pharmacy, Universitas Padjadjaran, Sumedang 45363, Indonesia.

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer, having a poor prognosis and rapid metastases. TNBC is characterized by the absence of estrogen, progesterone, and human epidermal growth receptor-2 (HER2) expressions and has a five-year survival rate. Compared to other breast cancer subtypes, TNBC patients only respond to conventional chemotherapies, and even then, with limited success. Read More

View Article and Full-Text PDF

Targeting Cell Cycle Progression in HER2+ Breast Cancer: An Emerging Treatment Opportunity.

Int J Mol Sci 2022 Jun 11;23(12). Epub 2022 Jun 11.

Translational Oncology Laboratory, Avera Cancer Institute, Sioux Falls, SD 57105, USA.

The development of HER2-targeted therapies has dramatically improved patient survival and patient management and increased the quality of life in the HER2+ breast cancer patient population. Due to the activation of compensatory pathways, patients eventually suffer from resistance to HER2-directed therapies and develop a more aggressive disease phenotype. One of these mechanisms is the crosstalk between ER and HER2 signaling, especially the CDK4/6-Cyclin D-Rb signaling axis that is commonly active and has received attention for its potential role in regulating tumor progression. Read More

View Article and Full-Text PDF

Trastuzumab and Doxorubicin Sequential Administration Increases Oxidative Stress and Phosphorylation of Connexin 43 on Ser368.

Int J Mol Sci 2022 Jun 7;23(12). Epub 2022 Jun 7.

Department of Pharmacy, University of Salerno, 84084 Fisciano, Italy.

Human epidermal growth factor receptor-2 (HER2) is overexpressed in up to 30% of breast cancer cases, causing a more aggressive tumour growth and poor prognosis. Trastuzumab, the humanized antibody targeted to HER2, increased the life expectancy of patients, but severe cardiotoxicity emerged as a long-term adverse effect. Clinical evidence highlights that Trastuzumab-induced cardiotoxicity drastically increases in association with Doxorubicin; however, the exact mechanisms involved remain incompletely understood. Read More

View Article and Full-Text PDF

Exploring the Biological and Physical Basis of Boron Neutron Capture Therapy (BNCT) as a Promising Treatment Frontier in Breast Cancer.

Cancers (Basel) 2022 Jun 18;14(12). Epub 2022 Jun 18.

Department of Radiation Oncology, Mayo Clinic Florida, Jacksonville, FL 32224, USA.

BNCT is a high LET radiation therapy modality that allows for biologically targeted radiation delivery to tumors while reducing normal tissue impacts. Although the clinical use of BNCT has largely been limited to phase I/II trials and has primarily focused on difficult-to-treat malignancies such as recurrent head and neck cancer and recurrent gliomas, recently there has been a renewed interest in expanding the use of BNCT to other disease sites, including breast cancer. Given its high LET characteristics, its biologically targeted and tumor specific nature, as well as its potential for use in complex treatment settings including reirradiation and widespread metastatic disease, BNCT offers several unique advantages over traditional external beam radiation therapy. Read More

View Article and Full-Text PDF

Anthracycline-Free Neoadjuvant Treatment in Patients with HER2-Positive Breast Cancer: Real-Life Use of Pertuzumab, Trastuzumab and Taxanes Association with an Exploratory Analysis of PIK3CA Mutational Status.

Cancers (Basel) 2022 Jun 18;14(12). Epub 2022 Jun 18.

Medical Oncology Unit, Department of Oncology, AUSL 04 Teramo, 64100 Teramo, Italy.

HER2 is considered one of the most traditional prognostic and predictive biomarkers in breast cancer. Literature data confirmed that the addition of pertuzumab to a standard neoadjuvant chemotherapy backbone (either with or without anthracyclines), in patients with human epidermal growth factor receptor 2 (HER2)-positive early breast cancer (EBC), leads to a higher pathological complete response (pCR) rate, which is known to correlate with a better prognosis. In this retrospective analysis, 47 consecutive patients with HER2-positive EBC received sequential anthracyclines and taxanes plus trastuzumab (ATH) or pertuzumab, trastuzumab and docetaxel (THP). Read More

View Article and Full-Text PDF

Post-Neoadjuvant Treatment in HER2-Positive Breast Cancer: Escalation and De-Escalation Strategies.

Cancers (Basel) 2022 Jun 18;14(12). Epub 2022 Jun 18.

Department of Gynecology and Obstetrics, University Hospital Schleswig-Holstein Campus Lübeck, 23562 Lübeck, Germany.

Patients with high-risk non-metastatic breast cancer are recommended for chemotherapy, preferably in the neoadjuvant setting. Beyond advantages such as a better operability and an improved assessment of individual prognosis, the preoperative administration of systemic treatment offers the unique possibility of selecting postoperative therapies according to tumor response. In patients with HER2-positive disease, both the escalation of therapy in the case of high-risk features and the de-escalation in patients with a low tumor load are currently discussed. Read More

View Article and Full-Text PDF